Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-4199 CR Extension Study for Bipolar I Depression
NCT05227209Phase 3Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of SEP-4199 in bipolar I disorder, sponsored by Sumitomo Pharma America. Started Mar 2022; status: terminated.
02
Drugs
SEP-4199
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT05227209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227209.